PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosi
暂无分享,去创建一个
N Harbeck | W Fett | S Loibl | P. Fasching | M. lenhard | S. Loibl | N. Harbeck | S. Hasmüller | M. Lenhard | M. Untch | V. Nekljudova | A. Lebeau | G. von Minckwitz | E. Stickeler | V. Müller | G. Konecny | C. Salat | G. Minckwitz | H. Lück | P. Fasching | M Untch | G von Minckwitz | C. Kurzeder | M Schmidt | G E Konecny | V Nekljudova | M. Beckmann | U Conrad | C Kurzeder | H-J Lück | E Stickeler | H Urbaczyk | B Liedtke | M W Beckmann | C Salat | V Müller | S Hasmüller | M Lenhard | A Lebeau | P A Fasching | M. Schmidt | W. Fett | U. Conrad | H. Urbaczyk | B. Liedtke | Marcus Schmidt | Volkmar Müller | Nadia Harbeck | C. Kurzeder | Christoph Salat | Annette Lebeau
[1] P. Fasching,et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. , 2009 .
[2] M. Zwahlen,et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.
[3] N Harbeck,et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] P. Fasching,et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.
[5] G. Rustin,et al. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Crawford,et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Andreas Schneeweiss,et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Fasching,et al. Abstract P1-11-03: Pathological Complete Response after Neoadjuvant Chemotherapy + Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial , 2010 .
[9] G. Schwarzer,et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. , 2006, Journal of the National Cancer Institute.
[10] J. Baselga,et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Norman Wolmark,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Schneeweiss,et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.